Scientists Filmed Immune Cells Eating Live Skin Cancer Cells For The First Time

For more than 15 years, immune checkpoint inhibitors have transformed the treatment of melanoma, the deadliest form of skin cancer. These drugs can trigger dramatic and long-lasting remissions, yet many patients see little or no benefit, and researchers still do not fully understand why.

New research published in the Journal of Experimental Medicine offers a striking clue. Using advanced live imaging, scientists captured immune cells called macrophages actively attacking and consuming living melanoma cells in real time, revealing a previously overlooked line of cancer defense.

Hot and Cold Tumors Explained

Melanoma tumors are often divided into two broad categories: “hot” and “cold.” Hot tumors contain large numbers of T cells — the immune system’s specialized cancer-fighting cells — and tend to respond well to checkpoint inhibitors that release inhibitory signals on these cells.

Cold tumors, by contrast, keep T cells inactive or prevent them from entering the tumor, making immunotherapy far less effective.

Dermatologist and researcher Yuki Keith, who treated melanoma patients in Japan, joined immunologist Tri Phan’s laboratory at the Garvan Institute in Sydney to investigate why so many tumors remain cold.

Their findings suggest that macrophages, long viewed as secondary immune players in cancer biology, may actually be central to whether a tumor can become responsive to immunotherapy.

The Overlooked Housekeepers of Immunity

Macrophages were first described in the early 20th century by Nobel Prize-winning scientist Ilya Mechnikov, who identified their role in phagocytosis — the process of engulfing harmful material.

These cells function as the body’s cleanup crew, removing dead cells, debris, and pathogens from tissues.

Because macrophages often reside permanently inside tissues rather than circulating in blood, their role in cancer was historically oversimplified. Modern imaging techniques, however, are revealing that macrophages are highly diverse depending on their location and environment.

The Garvan team identified several distinct macrophage populations in healthy skin. One subgroup marked by the protein CD169 was located in the hypodermis, the deeper layer beneath the skin.

These CD169-positive macrophages clustered tightly around melanoma tumors, almost forming a protective barrier at the tumor edge.

When researchers experimentally removed these macrophages in animal models, melanoma tumors grew more rapidly, suggesting the cells actively help restrain cancer growth.

Scientists Filmed Macrophages Eating Live Cancer Cells

To understand what these macrophages were doing, researchers used intravital two-photon microscopy, a sophisticated technique that allows scientists to observe living cells interacting deep inside tissue in real time.

What they saw surprised them.

The macrophages were not simply cleaning up dead tumor cells. Instead, they repeatedly attacked, nibbled at, and gradually engulfed living melanoma cells.

The process resembled a slow-motion assault, with immune cells persistently consuming pieces of active cancer over time.

Equally striking was that this attack appeared to occur independently of T cells and antibodies, which are usually considered the primary drivers of anti-cancer immunity.

The macrophages seemed capable of recognizing and attacking melanoma cells directly, revealing an underappreciated layer of innate immune defense against solid tumors.

To determine whether this also occurs in humans, the researchers collaborated with the Melanoma Institute Australia to examine patient tissue samples. They found similar clusters of CD169-positive macrophages positioned around human melanoma tumors, suggesting the same mechanism may operate in people.

From Cleanup Cells to Immune Coordinators

Macrophages do far more than remove debris. After digesting abnormal material, they can present fragments of it to T cells, effectively alerting the broader immune system to danger.

However, macrophages can also quietly dispose of material without triggering a larger immune response. Scientists still do not fully understand what determines whether macrophages remain passive cleaners or become active immune stimulators.

Because CD169-positive macrophages sit directly at the border between healthy tissue and cancer, researchers suspect they may play a major role in deciding whether tumors stay cold or become immunologically active.

If scientists can identify the signals that encourage these cells to both consume melanoma cells and activate T cells efficiently, they may eventually develop therapies capable of converting resistant tumors into immunotherapy-responsive ones.

Importantly, macrophages are abundant in many difficult-to-treat cancers, including glioblastoma and some breast cancers, making them an attractive therapeutic target.

Implications for Future Cancer Treatments

The findings add momentum to the growing field of macrophage-based immunotherapy.

Researchers are already exploring experimental treatments designed to enhance macrophage phagocytosis, block tumor signals that suppress macrophage activity, or engineer macrophages to recognize specific cancer markers.

Understanding macrophage behavior may also help explain why some patients fail to respond to checkpoint inhibitors despite having the appropriate immune targets on their T cells. If macrophages are not effectively presenting tumor antigens or creating a pro-inflammatory environment, T cells may never fully activate.

The Garvan team now plans to investigate the molecular pathways that allow CD169-positive macrophages to recognize and ingest living melanoma cells. Researchers are also studying how these cells communicate with T cells inside tumors and whether strengthening this interaction could improve existing immunotherapies.

Although the work remains at the preclinical stage, it highlights a broader shift in cancer research away from a purely T-cell-focused view of immunity toward a more integrated model that includes macrophages and other innate immune cells.

The researchers caution that macrophage-targeted therapies will require careful testing because these cells are essential for normal tissue maintenance and immune balance. Still, the visual evidence of live cancer cells being eaten in real time offers compelling proof that macrophages may become a major new frontier in melanoma treatment and cancer immunotherapy more broadly.